 Credit Suisse has raised the price target on Kura Oncology Inc NASDAQ: KURA to 29 from 27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose for ziftomenib should support an upside of 8-10share to their NPV. 